18F-FDG PET/CT vs. PET/MRI in Cancer Assessment

PET/MRI scanners are introduced and probed for their ability to improve cancer assessment relative to PET/CT.

Course ID: Q00491 Category:
Modalities: , , , ,

1.5

Satisfaction Guarantee

$24.00

View cart

Targeted CE per ARRT’s Discipline, Category, and Subcategory classification:
[Note: Discipline-specific Targeted CE credits may be less than the total Category A credits approved for this course.]

Nuclear Medicine Technology: 0.50
Procedures: 0.50
Endocrine and Oncology Procedures: 0.50

Outline

  1. Introduction
  2. Design of PET/MRI Systems
  3. Operational Considerations
  4. Clinical Indications for PET/MRI
    1. Head and Neck Cancer
    2. Lung Cancer and Pulmonary Lesions
    3. Gastrointestinal Cancer
    4. Gynecologic Cancer
    5. Breast Cancer
    6. Prostate Cancer
    7. Lymphoma
    8. Neuroendocrine Tumors
    9. Metastatic Bone Disease
    10. Pediatric Cancer
    11. Central Nervous System Tumors
    12. Mixed-Cancer Populations
  5. Summary and Future Perspectives

Objectives

Upon completion of this course, students will:

  1. identify the most important reason driving the success of PET/CT after integrated scanners became commercially available in 2000
  2. describe the primary focus of studies comparing PET/MRI and 18F-FDG PET/CT
  3. list the PET/MRI system designs that allow the individual modality components to be used independently
  4. list the PET/MRI system designs that allow for reduced imaging time and the least amount of image misregistration
  5. list the classes of tissue segmentation provided by MRI-based attenuation correction sequences
  6. understand the prerequisites for clinical adoption of PET/MRI
  7. identify the superiority of PET/MRI over PET/CT in prostate cancer
  8. describe the role of CT and MRI as first-line imaging modalities according to NCCN guidelines
  9. list the imaging modalities supported by NCCN guidelines for staging and restaging of head and neck cancer patients
  10. recognize the stages of small cell lung cancer for which 18F-FDG PET/CT is appropriate for additional work-up
  11. describe the size threshold of 18F-FDG-negative lung nodules that limits detection by PET/MRI
  12. identify the recommended imaging modality for T-staging of esophageal cancer
  13. identify the imaging modality that demonstrates the highest accuracy for N-staging of esophageal cancer
  14. identify the first-line imaging modality listed by NCCN guidelines for liver metastases of colorectal cancer
  15. list the imaging modalities used for initial diagnosis of uterine, ovarian, and cervical cancers
  16. describe the clinical settings in which MRI is considered for staging of breast cancer patients
  17. describe the use of PET/CT for staging of breast cancer
  18. understand the application of multiparametric MRI in the evaluation of recurrent prostate cancer
  19. list the PET tracers used in conjunction with PET/CT to identify sites of metastatic prostate cancer
  20. describe the diagnostic modality of choice for lymphomas that are not routinely 18F-FDG-avid
  21. compare the sensitivities of DWI, PET/MRI and PET/CT in the identification of 18F-FDG-avid nodal groups
  22. identify the imaging technique that is considered the standard of care for assessing neuroendocrine tumor patients
  23. compare the sensitivities of imaging modalities for the detection of early bone lesions and marrow-based metastases
  24. describe the body region were lesion detection rates with PET/CT are slightly better than those with PET/MRI
  25. identify the imaging modality that is considered to be the gold standard for imaging central nervous system cancer